Show simple item record

dc.contributor.authorScheid, Christof
dc.contributor.authorPettengell, Ruth
dc.contributor.authorGhielmini, Michele
dc.contributor.authorRadford, John A
dc.contributor.authorMorgenstern, Godfrey R
dc.contributor.authorStern, Peter L
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-12-10T14:49:30Z
dc.date.available2010-12-10T14:49:30Z
dc.date.issued1995-06
dc.identifier.citationTime-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. 1995, 15 (6):901-6 Bone Marrow Transplanten
dc.identifier.issn0268-3369
dc.identifier.pmid7581089
dc.identifier.urihttp://hdl.handle.net/10541/117679
dc.description.abstractChemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. We investigated the recovery of cellular immune functions after high-dose chemotherapy and PBPC transplantation in 5 patients with high grade non-Hodgkin's lymphoma. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10-14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 x 10(9)/l between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by IL-2 to exert high levels of cytotoxicity.
dc.language.isoenen
dc.subjectAnticancerous Combined Chemotherapy Protocolsen
dc.subjectHaemapoietic Stem Cell Transplantationen
dc.subjectLeukaemiaen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBleomycin
dc.subject.meshBone Marrow Diseases
dc.subject.meshBusulfan
dc.subject.meshCarmustine
dc.subject.meshCombined Modality Therapy
dc.subject.meshCyclophosphamide
dc.subject.meshCytarabine
dc.subject.meshDoxorubicin
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHumans
dc.subject.meshKiller Cells, Lymphokine-Activated
dc.subject.meshKiller Cells, Natural
dc.subject.meshLeukapheresis
dc.subject.meshLymphocyte Count
dc.subject.meshLymphocyte Subsets
dc.subject.meshLymphoma, B-Cell
dc.subject.meshLymphoma, Non-Hodgkin
dc.subject.meshMale
dc.subject.meshMelphalan
dc.subject.meshMesna
dc.subject.meshMiddle Aged
dc.subject.meshPodophyllotoxin
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.subject.meshVincristine
dc.titleTime-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Immunology, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalBone Marrow Transplantationen
html.description.abstractChemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. We investigated the recovery of cellular immune functions after high-dose chemotherapy and PBPC transplantation in 5 patients with high grade non-Hodgkin's lymphoma. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10-14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 x 10(9)/l between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by IL-2 to exert high levels of cytotoxicity.


This item appears in the following Collection(s)

Show simple item record